Gamma Delta T Cell Therapy for Ph+ Leukemia
Author Information
Author(s): Gabrielle M. Siegers, Tania C. Felizardo, A. Mark Mathieson, Yoko Kosaka, Xing-Hua Wang, Jeffrey A. Medin, Armand Keating
Primary Institution: Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
Hypothesis
Can in vitro-expanded human gamma delta T cells effectively treat Ph+ leukemia in a xenogeneic model?
Conclusion
In vitro-expanded gamma delta T cells showed selective cytotoxicity against Ph+ leukemia cells and decreased leukemia burden in treated mice.
Supporting Evidence
- Gamma delta T cells were expanded in vitro and shown to be cytotoxic against Ph+ leukemia cell lines.
- Therapy with gamma delta T cells resulted in decreased leukemia burden in treated mice.
- Expanded gamma delta T cells persisted in the mouse model for up to 33 days.
Takeaway
Scientists are testing a new type of immune cell therapy to help fight a specific kind of leukemia, and it seems to work better than traditional methods.
Methodology
The study involved expanding gamma delta T cells from healthy donors and testing their effectiveness against Ph+ leukemia cells in a mouse model.
Potential Biases
Potential bias due to the small number of donors and the specific model used.
Limitations
The study had a limited sample size and the therapy did not show a significant survival advantage.
Participant Demographics
Healthy adult donors were used to obtain gamma delta T cells.
Statistical Information
P-Value
p=0.3563
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website